Wealth Enhancement Advisory Services
SNDX icon

Wealth Enhancement Advisory Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$471K Sell
19,950
-2,595
-12% -$54K ﹤0.01% 2740
2026
Q1 		$567K Buy
22,545
+2,350
+12% +$51.1K ﹤0.01% 2221
2025
Q4 		$411K Buy
20,195
+7,310
+57% +$128K ﹤0.01% 2635
2025
Q3 		$212K Buy
+12,885
New +$169K ﹤0.01% 3086
2025
Q2 		– Sell
-13,172
Closed -$162K – 3476
2025
Q1 		$162K Buy
+13,172
New +$186K ﹤0.01% 2670

Other funds holding SNDX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Wealth Enhancement Advisory Services's SNDX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Syndax Pharmaceuticals (SNDX) stake by 12% in Q2 2026, selling an estimated $54K and leaving 19,950 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Wealth Enhancement Advisory Services first reported a position in SNDX in Q1 2025 and has held it in 5 quarters since. The position peaked at $567K in Q1 2026. 24 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 19,950 shares of Syndax Pharmaceuticals worth $471K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 2,595 Syndax Pharmaceuticals shares in Q2 2026, an estimated $54K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2740 holding.
  • Wealth Enhancement Advisory Services first reported a position in Syndax Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Wealth Enhancement Advisory Services's Syndax Pharmaceuticals position peaked at $567K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.